MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors

Circulation

Volumn 127, Issue 21, 2013, Pages 2097-2106

  Ganesan, Jayavarshni ^a,b   Ramanujam, Deepak ^a   Sassi, Yassine ^a   Ahles, Andrea ^a   Jentzsch, Claudia ^a   Werfel, Stanislas ^a   Leierseder, Simon ^a,b   Loyer, Xavier ^a,b,f   Giacca, Mauro ^c   Zentilin, Lorena ^c   Thum, Thomas ^d   Laggerbauer, Bernhard ^a   Engelhardt, Stefan ^a,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^f PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Cardiomyocytes; Gene therapy; Hypertrophy; MicroRNA

Indexed keywords

GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 378; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BIOINFORMATICS; CELL ISOLATION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; MOUSE; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THORACIC AORTA;

CARDIOMYOCYTES; GENE THERAPY; HYPERTROPHY; MICRORNA;

ADENOVIRIDAE; ANIMALS; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GRB2 ADAPTOR PROTEIN; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOCYTES, CARDIAC; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOMEDIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84878294979     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000882     Document Type: Article

References (42)

1. Bartel D P. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-233.
2. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012; 148: 1172-1187.
3. Jentzsch C, Leierseder S, Loyer X, Flohrschütz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B, Engelhardt S. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol. 2012; 52: 13-20.
4. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foà R, Schliwka J, Fuchs U, Novosel A, Müller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007; 129: 1401-1414.
5. *) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab. 2010; 12: 352-361.
6. Kahai S, Lee SC, Lee DY, Yang J, Li M, Wang CH, Jiang Z, Zhang Y, Peng C, Yang BB. MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One. 2009; 4:e7535.
7. *. Proc Natl Acad Sci U S A. 2012; 109: 15330-15335.
8. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A. 2007; 104: 20350-20355.
9. Feng M, Li Z, Aau M, Wong CH, Yang X, Yu Q. Myc/miR-378/TOB2/ cyclin D1 functional module regulates oncogenic transformation. Oncogene. 2011; 30: 2242-2251.
10. Gagan J, Dey BK, Layer R, Yan Z, Dutta A. MicroRNA-378 targets the myogenic repressor MyoR during myoblast differentiation. J Biol Chem. 2011; 286: 19431-19438.
11. Fang J, Song XW, Tian J, Chen HY, Li DF, Wang JF, Ren AJ, Yuan WJ, Lin L. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. Apoptosis. 2012; 17: 410-423.
12. Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, Nagalingam RS, Gupta M. A novel cardiomyocyte enriched microRNA, miR-378, targets IGF1R: implications in postnatal cardiac remodeling and cell survival. J Biol Chem. 2012; 287: 12913-12926.
13. Frost RJ, Engelhardt S. A secretion trap screen in yeast identifies protease inhibitor 16 as a novel antihypertrophic protein secreted from the heart. Circulation. 2007; 116: 1768-1775.
14. Merkle S, Frantz S, Schön MP, Bauersachs J, Buitrago M, Frost RJ, Schmitteckert EM, Lohse MJ, Engelhardt S. A role for caspase-1 in heart failure. Circ Res. 2007; 100: 645-653.
15. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991; 88: 8277-8281.
16. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999; 96: 7059-7064.
17. Seeland U, Selejan S, Engelhardt S, Müller P, Lohse MJ, Böhm M. Interstitial remodeling in beta1-adrenergic receptor transgenic mice. Basic Res Cardiol. 2007; 102: 183-193.
18. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007; 116: 258-267.
19. Kowarsch A, Preusse M, Marr C, Theis FJ. miTALOS: analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs. RNA. 2011; 17: 809-819.
20. Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskämper J, Westermann D, Bisping E, Ly H, Wang X, Kawase Y, Chen J, Liang L, Sipo I, Vetter R, Weger S, Kurreck J, Erdmann V, Tschope C, Pieske B, Lebeche D, Schultheiss HP, Hajjar RJ, Poller WC. Long-term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009; 119: 1241-1252.
21. Hulot JS, Fauconnier J, Ramanujam D, Chaanine A, Aubart F, Sassi Y, Merkle S, Cazorla O, Ouillé A, Dupuis M, Hadri L, Jeong D, Mühlstedt S, Schmitt J, Braun A, Bénard L, Saliba Y, Laggerbauer B, Nieswandt B, Lacampagne A, Hajjar RJ, Lompré AM, Engelhardt S. Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation. 2011; 124: 796-805.
22. Latronico MV, Condorelli G. microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood). 2011; 236: 125-131.
23. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc Res. 2006; 72: 51-59.
24. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22: 153-183.
25. Kehat I, Molkentin JD. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci. 2010; 1188: 96-102.
26. Ueyama T, Kawashima S, Sakoda T, Rikitake Y, Ishida T, Kawai M, Yamashita T, Ishido S, Hotta H, Yokoyama M. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol. 2000; 32: 947-960.
27. Lozano J, Xing R, Cai Z, Jensen HL, Trempus C, Mark W, Cannon R, Kolesnick R. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res. 2003; 63: 4232-4238.
28. Clapéron A, Therrien M. KSR and CNK: two scaffolds regulating RASmediated RAF activation. Oncogene. 2007; 26: 3143-3158.
29. Rabizadeh S, Xavier RJ, Ishiguro K, Bernabeortiz J, Lopez-Ilasaca M, Khokhlatchev A, Mollahan P, Pfeifer GP, Avruch J, Seed B. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem. 2004; 279: 29247-29254.
30. Oceandy D, Pickard A, Prehar S, Zi M, Mohamed TM, Stanley PJ, Baudoin-Stanley F, Nadif R, Tommasi S, Pfeifer GP, Armesilla AL, Cartwright EJ, Neyses L. Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation. 2009; 120: 607-616.
31. Zhang S, Weinheimer C, Courtois M, Kovacs A, Zhang CE, Cheng AM, Wang Y, Muslin AJ. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest. 2003; 111: 833-841.
32. McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem. 2004; 279: 4782-4793.
33. Delaughter MC, Taffet GE, Fiorotto ML, Entman ML, Schwartz RJ. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 1999; 13: 1923-1929.
34. Ceci M, Ross J Jr, Condorelli G. Molecular determinants of the physiological adaptation to stress in the cardiomyocyte: a focus on AKT. J Mol Cell Cardiol. 2004; 37: 905-912.
35. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M, Muslin AJ. Akt1 is required for physiological cardiac growth. Circulation. 2006; 113: 2097-2104.
36. DeBosch B, Sambandam N, Weinheimer C, Courtois M, Muslin AJ. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem. 2006; 281: 32841-32851.
37. Sussman MA, Völkers M, Fischer K, Bailey B, Cottage CT, Din S, Gude N, Avitabile D, Alvarez R, Sundararaman B, Quijada P, Mason M, Konstandin MH, Malhowski A, Cheng Z, Khan M, McGregor M. Myocardial AKT: the omnipresent nexus. Physiol Rev. 2011; 91: 1023-1070.
38. Mestdagh P, Boström A, Impens F, Fredlund E, Peer V, De Antonellis P, Von Stedingk K, Ghesquière B, Schulte S, Dews M, Thomas-tikhonenko A, Schulte JH, Zollo M, Schramm A, Gevaert K, Axelson H, Vandesompele J. The miR-17-92 microRNA cluster regulates multiple components of the TGFbeta-pathway in neuroblastoma. Mol Cell. 2011; 40: 762-773.
39. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, Becker KG, Gorospe M, Hide W, Lieberman J. miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell. 2009; 35: 610-625.
40. Gladka MM, da Costa Martins PA, De Windt LJ. Small changes can make a big difference: microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol. 2012; 52: 74-82.
41. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, Cimino V, De Marinis L, Frustaci A, Catalucci D, Condorelli G. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation. 2009; 120: 2377-2385.
42. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005; 33: 5394-5403.